Accord Healthcare To Acquire Prothya Biosolutions in Global Expansion Strategy

Deal News | Aug 12, 2025 | PR Newswire Cision Accord Healthcare

Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the signing of a definitive agreement to acquire Prothya Biosolutions Belgium BV and all its subsidiaries. Prothya Biosolutions, with its holdings in the Netherlands and Belgium, is a leading company specializing in plasma-derived medicinal products, an industry critical for developing therapies that aid in various health conditions. The acquisition is currently pending regulatory approvals and seeks to solidify Intas's global presence in the PDMP market. The deal will leverage Prothya's experience with enzymatic plasma fractionation and distribution networks, enhancing Intas's capabilities with additional plasma fractionation capacity and expanding its global sales footprint. BofA Securities is advising Accord, and Evercore is advising Prothya in this transaction.

Sectors

  • Pharmaceuticals
  • Biotechnology

Geography

  • India – Intas Pharmaceuticals, the acquiring company, is based in Ahmedabad, India.
  • Netherlands – Prothya Biosolutions Belgium BV, the target company, has operations and its main headquarters in Amsterdam, Netherlands.
  • Belgium – Prothya Biosolutions also operates out of Belgium, making it part of the geographical relevance for the acquisition.
  • Global – The acquisition will expand Intas Pharmaceuticals' presence to a global scale, impacting markets in over 85 countries.

Industry

  • Pharmaceuticals – The article discusses the acquisition of a company involved in the manufacturing of plasma-derived medicinal products, which is part of the pharmaceutical industry.
  • Biotechnology – Prothya Biosolutions operates in the biotechnological sector involving plasma fractionation and medicinal products development derived from biological sources.

Financials

  • 30 billion USD – Current estimated global market for PDMP (Plasma-Derived Medicinal Products).
  • 50 billion USD – Projected valuation of the global PDMP market by the year 2035.

Participants

NameRoleTypeDescription
Accord Plasma B.V.Acquiring CompanyCompanyA subsidiary of Intas Pharmaceuticals focused on plasma-derived medicinal products.
Intas PharmaceuticalsAcquiring CompanyCompanyA leading vertically integrated pharmaceutical company based in India.
Prothya Biosolutions Belgium BVTarget CompanyCompanyA leading company specializing in plasma-derived medicinal products with main headquarters in Amsterdam and Brussels.
BofA SecuritiesFinancial AdvisorCompanyServed as the exclusive financial advisor for Accord Plasma B.V. in this transaction.
EvercoreFinancial AdvisorCompanyServed as the exclusive financial advisor for Prothya Biosolutions in this transaction.
Binish ChudgarChairmanPersonChairman of Intas Pharmaceuticals and Accord.
Nir EpsteinCEOPersonCEO of Prothya Biosolutions.